Lausanne, Switzerland – April 15, 2016 – Debiopharm International SA (Debiopharm), a Swiss-based company, part of Debiopharm Group™, today announces that non-clinical data on the clinical-stage investigational compound Debio 1347/CH5183284 (FGFR 1,2,3 inhibitor) will be presented at the 2016 Annual Meeting of the American Association for Cancer Research (AACR) taking place in New Orleans, by Debiopharm and Chugai Pharmaceutical Co., Ltd.
Debio 1347/CH5183284 is currently being evaluated in Europe and USA, in a first-in-man phase I trial in patients with advanced solid tumors displaying FGFR 1, 2, or 3 genetic alterations. Debiopharm is investigating patient selection criteria with the aim of enabling personalized treatments with Debio 1347/CH5183284 associated with a companion diagnostic.
‘We are very pleased to present this latest set of scientific data relating to our FGFR inhibitor, which further reinforces Debiopharm’s commitment to the advancement of personalized therapies which have the potential to improve and extend the lives of individuals living with cancer’, said Dr Nigel McCracken, Vice President, Translational Medicine, Debiopharm International SA.
About Debiopharm International SA
Debiopharm Group™ is a Swiss-based global biopharmaceutical group of four companies active in drug development, GMP manufacturing of proprietary drugs, diagnostics and investment management. Debiopharm International SA is focused on the development of prescription drugs that target unmet medical needs. The company in-licenses and develops promising drug candidates. The products are commercialized by pharmaceutical out-licensing partners to give access to the largest number of patients worldwide.